Real-world impact across clinical development

Trial design and protocol development need to be improved from both the biotech and the investor perspectives. Protocol development is a critical but challenging process due to its complexity, rapid changes in the regulatory and treatment environment, and the constraints biotechs are facing. I find AIRA extremely valuable because it allows teams to access and evaluate design pathways and options based on their strategic goals and constraints, understand trade-offs, and develop the regulatory submission package more accurately and quickly.

“

AIRA took us from the earliest strategic planning all the way through drafting the actual documents — all in one place. We're planning to keep using it as we move into our next phases.

Using AIRA feels remarkably close to sitting down in a room with an experienced team and making study design decisions.

AIRA can identify relevant evidence, regulatory considerations, and new strategic ideas within minutes. I am impressed by the depth of AIRA's clinical and regulatory reasoning. It considers both FDA and EMA expectations, asks the right questions, and helps translate an initial study concept into a well-supported protocol.

“

From my perspective as a drug developer, AIRA is much more than a tool for writing documents. It acts as a transparent thinking partner. Its study design suggestions and proposed revisions help us challenge assumptions, connect the scientific rationale to the clinical plan, and identify risks early. This allows us to design and advance trials with greater confidence.

“

For a biotech, AIRA changes the operational and financial equation of clinical development. It helps us move critical work forward faster, make better-informed strategic decisions, and do more without immediately having to grow the team or rely heavily on outsourcing.

Trial design and protocol development need to be improved from both the biotech and the investor perspectives. Protocol development is a critical but challenging process due to its complexity, rapid changes in the regulatory and treatment environment, and the constraints biotechs are facing. I find AIRA extremely valuable because it allows teams to access and evaluate design pathways and options based on their strategic goals and constraints, understand trade-offs, and develop the regulatory submission package more accurately and quickly.

“

AIRA took us from the earliest strategic planning all the way through drafting the actual documents — all in one place. We're planning to keep using it as we move into our next phases.

Using AIRA feels remarkably close to sitting down in a room with an experienced team and making study design decisions.

AIRA can identify relevant evidence, regulatory considerations, and new strategic ideas within minutes. I am impressed by the depth of AIRA's clinical and regulatory reasoning. It considers both FDA and EMA expectations, asks the right questions, and helps translate an initial study concept into a well-supported protocol.

“

From my perspective as a drug developer, AIRA is much more than a tool for writing documents. It acts as a transparent thinking partner. Its study design suggestions and proposed revisions help us challenge assumptions, connect the scientific rationale to the clinical plan, and identify risks early. This allows us to design and advance trials with greater confidence.

“

For a biotech, AIRA changes the operational and financial equation of clinical development. It helps us move critical work forward faster, make better-informed strategic decisions, and do more without immediately having to grow the team or rely heavily on outsourcing.